Lv3
220 积分 2023-09-03 加入
Diverse alterations associated with resistance to KRAS(G12C) inhibition
2小时前
已完结
RAS-targeted therapies: is the undruggable drugged?
2小时前
已完结
Targeting KRAS in cancer
3小时前
已完结
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
2个月前
已完结
Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis
2个月前
已完结
Consensus on the management of cutaneous adverse reactions to anti-tumor drugs
2个月前
已完结
Cancer incidence and mortality in China, 2022
4个月前
已完结
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
5个月前
已完结
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies
5个月前
已完结
The current state of the art and future trends in RAS-targeted cancer therapies
5个月前
已完结
皖公网安备34019202002308
